Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations

The evidence from 15 randomized prospective studies supports the combined use of a GLP-1 receptor agonist with basal insulin in a broad range of patients with uncontrolled type 2 diabetes (Drugs)